The Colony Stimulating Factors Market is expected to grow at a 7.90% CAGR during the forecast period for 2024-2031.
Colony stimulating factors (CSFs) are proteins that resemble hormones and encourage the development of immune cells that can fight infections. Human bodies manufacture CSFs from various cells, which can travel throughout the body and attach to cells with specific CSF receptors. CSFs can stimulate the synthesis of immune cells, which makes them useful as medications to boost the production of white blood cells. This could be a life-saving medication for patients whose immune systems have been destroyed by chemotherapy or specific immunodeficiency diseases. The primary factors propelling the growth of the global market for colony-stimulating factors are the rise in governmental funding for healthcare, rising cancer prevalence, and awareness of the availability of different cancer treatment alternatives. The growing need for prophylactic colony-stimulating factors is another significant reason for the market's expansion.
It is projected that improvements and advancements in genomics technology and healthcare will drive market expansion throughout the forecast period. Ongoing research and development of new cancer medicines and treatments for their side effects drive market growth. However, the market's growth is constrained by stringent government regulations for the approval of any new treatment options. The high cost is one of the critical obstacles limiting the CSF market from growing.
Market Segmentation:
The Colony Stimulating Factors market is segmented on type, drug, application, dosage, route of administration, end-users and distribution channel. Based on type, the market is segmented into Macrophage–Colony-Stimulating Factor (M-CSF), Multiple-Colony-Stimulating Factor or Interleukin 3 (IL-3), Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF) and Granulocyte–Colony-Stimulating Factor (G-CSF). Based on the drug, the Colony Stimulating Factors are segmented into Pegfilgrastim, Tbo-filgrastim, Sargramostim and Filgrastim. Based on the application, the Colony Stimulating Factors are segmented into Aplastic Anemia, Bone Marrow Transplantation, Neutropenia, Neutropenia Associated with Chemotherapy, Neutropenia Associated with Radiation and Peripheral Progenitor Cell Transplantations. Based on dosage, the Colony Stimulating Factors are segmented into Injection, Tablets, Capsules and Others. Based on route of administration, the market is segmented into Intravenous, Subcutaneous, Oral and Others. Based on end-user, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on distribution channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others.
Based On Type, The Granulocyte–Colony-Stimulating Factor (G-CSF) Segment Is Accounted As A Significant Contributor To The Colony Stimulating Factors Market.
Based on type, the market is segmented into Macrophage–Colony-Stimulating Factor (M-CSF), Multiple-Colony-Stimulating Factor or Interleukin 3 (IL-3), Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF) and Granulocyte–Colony-Stimulating Factor (G-CSF). The Granulocyte–Colony-Stimulating Factor (G-CSF) segment dominated the market. Following chemotherapy, the drug Granulocyte Colony-stimulating Factor (G-CSF) is used to treat cancer. Granulocyte-colony stimulating factor (G-CSF) is a glycoprotein that encourages the production of stem cells and granulocytes in the bone marrow and their release into the blood.
The Pegfilgrastim Segment Witnessed Growth At A Rapid Rate.
Based on the drug, the Colony Stimulating Factors are segmented into Pegfilgrastim, Tbo-filgrastim, Sargramostim and Filgrastim. The Pegfilgrastim segment dominated the market. Treating neutropenia (low white blood cells) brought on by cancer medications involves the injection of pegfilgrastim. It is a man-made version of a substance known as a colony-stimulating factor created naturally in your body. White blood cell production in the bone marrow is boosted by pegfilgrastim.
The North America Colony Stimulating Factors Market Holds A Significant Regional Revenue Share.
The North America Colony Stimulating Factors market is expected to register the highest market share in revenue in the near future. Some factors contributing to its highest share include the availability of well-established healthcare facilities and many individuals suffering from blood disorders. Furthermore, increased R&D initiatives to create new products will likely boost growth during the projection period. In addition, Asia Pacific is projected to grow rapidly in the global Colony Stimulating Factors market because of rising chronic illness occurrences, rising per capita income, greater access to healthcare facilities, treatment rates for GWCF medications such as granulocyte colony-stimulating (G-CSF) factor have increased. Additionally, growing public awareness of chronic diseases will fuel demand in this region.
Competitive Landscape
Some major key players in the Colony Stimulating Factors Market:
- Intas Pharmaceuticals Ltd.,
- Sanofi,
- Novartis AG,
- Teva Pharmaceutical Industries Ltd.,
- Pfizer, Inc.,
- GlaxoSmithKline plc,
- Biocon,
- Reddy's Laboratories Ltd.,
- Amgen Inc.,
- Merck KGaA,
- Takeda Pharmaceutical Company Limited,
- Thermo Fisher Scientific Inc.,
- Stada Arzneimittel AG,
- Emcure Pharmaceuticals Limited.,
- Celltrion, Inc,
- Biocad,
- Coherus BioSciences,
- Johnson & Johnson Private Limited,
- Eli Lilly and Company
- Abbott
Colony Stimulating Factors Market Report Scope
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 7.90% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, Application, Drug, Dosage, Route of Administration, Distribution Channel, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Intas Pharmaceuticals Ltd., Sanofi, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., GlaxoSmithKline plc, Biocon, Dr. Reddy's Laboratories Ltd., Amgen Inc., Merck KGaA, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., Stada Arzneimittel AG, Emcure Pharmaceuticals Limited., Celltrion, Inc, Biocad, Coherus BioSciences, Johnson & Johnson Private Limited, Eli Lilly and Company and Abbott. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
